Pancreatic carcinoma, a type of malignant tumor of the pancreas with a high mortality rate, accounts for two to three percent of all malignant cancers. This kind of cancer is generally not diagnosed until an advanced stage, partly because the symptoms are nonspecific. The tumors have a tendency to metastasize aggressively, which makes this type of cancer so dangerous. To date, there has been no screening method available to detect pancreatic cancer early on, as is done with breast and colon cancer, for example. This means there is great need for a method of early diagnosis that can reliably detect not only pancreatic cancer but other tumors of the gastrointestinal tract as non-invasively as possible and with high accuracy. This is where the research done by the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB comes in: The In-vitro Diagnostics department, headed by Kai Sohn, has established an innovative method for early detection of pancreatic cancer in cooperation with the Universitätsklinikum Erlangen university medical center and a company called GeneData. The new method is based on complex next-generation sequencing (NGS) technology, a high-throughput approach to sequencing nucleic acids that makes it possible to sequence and analyze millions of DNA fragments simultaneously. The project received funding from the German Federal Ministry of Research, Technology and Space.

Method allows doctors to differentiate between different tumors of the gastrointestinal tract

As part of a clinical study conducted in collaboration with Georg Weber, a professor at the Universitätsklinikum Erlangen, patients who either had pancreatic cancer at various stages or a condition called non-malignant pancreatitis were recruited for a proof-of-concept study. Blood samples from these patients were analyzed for clinical validation purposes. “We demonstrated that our method allows researchers not only to tell healthy patients apart from those with tumors but also to distinguish among different gastrointestinal tract tumors,” Sohn says, highlighting the advantages of the innovative method. It will allow physicians to determine whether a certain DNA signature is specific to a disease. In the process, the cell-free DNA isolated from the plasma is screened for relevant methylation patterns. “The differentiation is successful because the methylation pattern in the genome of the pancreas differs from that of an immune cell, for example. The methylation also indicates a cell’s physiological condition,” Sohn explains.

The new method also makes it possible to distinguish a malignant tumor of the pancreas from a benign inflammation of the pancreas known as pancreatitis. The symptoms are very similar at first, but the treatment is completely different. In the study, the researchers were even able to classify non-malignant early stages based on specific methylation patterns in some cases.

As the next step, Sohn and his team are now working to analyze patient samples from different medical centers as part of a multicenter study with the ultimate goal of making this method a routine part of clinical practice.